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I- INTRODUCTION 
1.1 Arachidonic acid cascade  
Arachidonic acid (AA) is a polyunsaturated fatty acid (AA, 5, 8, 11, 14-eicosatetraenoic acid) 
present in cell membrane phospholipids and released upon activation of phospholipase A2. AA 
can be re-incoporated in the membranes or distributed outside the cell and it is a substrate for 
cyclooxygenases (COXs) and lipoxygenases (LOXs). 
 
COXs are responsible for the conversion of AA into cyclic endoperoxide intermediates 
prostaglandin G2 and H2 (PGG2-PGH2),which are the precursor for the biosynthesis of the following 
prostanoids: other PGs (PGD2, PGE2, PGF2α), prostacyclin (PGI2) and thromboxane (TXA2) 
biosynthesis (Fig 1). Prostanoids exert diverse functions as: pain response, maturation for ovulation 
and fertilization, fever generation, inhibition of gastric acid secretion, bone resorption (PGE2), 
modulation of platelets aggregation (PGI2 and TXA2), alteration of smooth muscle tone (PGE2, PGI2 
and TXA2), leukocytes infiltration at the inflammatory site (PGD2), uterine smooth muscle 
contraction (PGF2) [Funk CD., 1993]. 
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Fig 1. The arachidonic acid cascade [Hoxha M. et al., 2014] 
 
LOX are classified according to the number of the carbon subjected to dioxygenation as well as 
their stereoselectivity that can be either ―S‖ or ―R‖. The main human LOXs are 5-LOX, 12-LOX 
and 15-LOX. 5-LOX, in particular, transform the AA in 5-hydroperoxyeicosatetraenoic acid (5-
HPETE) by oxygenation at carbon 5, which, in turn, can bring to further production of 
leukotrienes (LTs) (Fig 2). 5-LO-activating protein (FLAP) should be co-localized with 5-LOX 
at the nuclear envelope for the LTs synthesis [Evans JF. et al., 2008]. LTA4 is a precursor of the 
production of LTs, a product of removal of hydrogen at carbon 10 from 5-HpETE [Shimizu T. et 
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al., 1984; Rådmark O. and Samuelsson B., 2009]. LTA4 can follow two different pathways, as it 
can be a substrate for LTA4 hydrolase leading to the production of LTB4 [Haeggstro¨m JZ., 
2004] or be a substrate for LTC4 synthase (LTC4S) leading to the production of LTC4, product 
of coniugation of LTA4 with glutathione [Austen KF., 2007]. LTD4 is formed by metabolization 
of LTC4 by glutamyl transpeptidase, and subsequently a serum dipeptidase can bring to the 
production of LTE4 from LTD4. LTs are classified in two groups: the first represented by LTB4, 
and the second by peptide leukotrienes (cysteinyl-LTs) such as LTC4, LTD4, and LTE4, based on 
the fact that they display a cysteinyl group at carbon 6.  
 
 
 
 
Fig 2. Biosynthesis and chemical structures of endogenous leukotriene receptor agonists, derived 
from arachidonic acid. [Ba¨ ck M. et al., 2007] 
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1.2 NSAIDs: Nonsteroidal anti-inflammatory drugs 
 
Nonsteroidal anti-inflammatory drugs are a class of drugs that display anti-inflammatory, analgesic 
and antipyretic activity due to the inhibition of the COX enzymes. There are two isoforms of COX, 
that vary by two aminoacid at their COXs catalytic sites [Vane JR. et al., 1998]; COX-1 the 
constitutive enzyme, recognized also as the housekeeper enzyme is believed to be responsible for 
the haemostatic integrity and gastric cytoprotection and the COX-2, the inducible enzyme, which is 
also constitutively expressed in some types of cells, like, kidney and endothelial cells [Smith W.L. 
et al., 2000, Morita I., 2002] is mainly expressed in response to inflammatory stimuli.The 
development and commercialization of Aspirin, the gold standard NSAID, which is an irreversible 
inhibitor of both isoforms of COX, disclosed an important side effect that belongs to NSAIDs, i.e. 
the gastric-lesivity, like, bleeding and ulcers [Laine L. et al., 2008]. These effects are mainly related 
to the inhibition of COX-1 enzyme, in particular to the inhibition of the local synthesis of the gastric 
mucosa cytoprotective PGE2, as well as to the NSAID storage inside the intestinal enterocytes 
[Matsui H. et al., 2011] and to the local lesion caused by the acidic properties of the drugs.  
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1.3 COXIBs: COX-2 selective inhibitors 
 
The necessity to minimize the gastrointestinal (GI) toxicity induced by the conventional NSAIDs 
and the discovery of a second isoform of COX lead to the quick development of a new class of 
drugs. The ’90s were very significant years for the development of a second generation of 
NSAIDs, which were named as COX-2 selective inhibitors or COXIBs. A new alternative for 
patients having osteoarthritis and rheumatoid arthritis was proposed, so Celecoxib (Celebrex) 
and Rofecoxib (Vioxx) were the first COXIBs used in therapy [FitzGerald GA. and Patrono C., 
2001]. The enthusiasm that accompanied the COXIB development, did not last longer. In fact, in 
2004 VIOXX was withdrawn from the market for increasing the risk of cardiovascular (CV) 
events, such as myocardial infarction (MI), and stroke. In a short time, this increase in CV 
adverse effects was related not only to COXIBs but also to the use of classical unselective 
NSAIDs [Hippisley-Cox J. et al., 2005][Kearney PM. et al., 2006][Warner TD. and Mitchell JA., 
2008][Bresalier R.S. et al., 2005][Solomon S.D. et al., 2005], which led to a re-evaluation of the 
whole class of NSAIDs. Eventhough COXIBs reached their goal in reducing the GI side effects 
caused by conventional NSAIDs, as evidenced by several clinical studies [Bombardier C. et al., 
2000; Silverstein FE. et al., 2000], they led to inevitable CV warnings. The withdrawn of 
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VIOXX, based on the Adenomatous Polyp Prevention on Vioxx (APPROVe) trial [Bresalier 
R.S. et al., 2005] that highlighted the severe CV effects [Grosser T. et al., 2006], was followed 
by the withdrawn of Valdecoxib (Bextra), and moreover, other COXIBs like etoricoxib never 
reached the FDA for further approvation.  
In an effort to answer the question, why these compounds gave rise to CV side effects, several 
hypothesis were proposed, one of which, known as the imbalance theory, correlated the COXIBs 
with the decrement of the PGI2 synthesis, possessing antiaggregatory properties, while 
maintaining unaltered TXA2 level, a potent platelet activator [Fitzgerald GA., 2004]. The reason 
behind this hypothesis was related to a study conducted in patients taking celecoxib and 
rofecoxib [Mc Adam B.F. et al., 1999] that presented decreased urinary excretion of the main 
PGI2 metabolite, 2,3 – dinor 6-keto PGF1α, and on the other hand, unaltered level of the TXB2, 
the urinary metabolite of TXA2 [Catella-Lawson F. et al., 1999]. Other potential mechanism can 
also be related to the shunt of AA towards the 5-LOX pathway, leading to the production of 
specific mediators concerned to CV events, or even the increase in LDL, as observed in patients 
treated with rofecoxib, taking also into consideration the fact that the effect and toxicity depend 
on the individual response. 
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Later on, it was suggested that the CV risk was not only an issue of COXIB alone, but also of 
traditional NSAIDs. The Arthritis Research and Gastrointestinal Event Trial (TARGET study) 
found that the CV risk, such as stroke, MI as well as CV death, was quite the same between 
patients taking a COXIB, like, lumiracoxib (0.65%) or a classical NSAID (0-55%) [Schnitzer TJ. 
et al., 2004]. Moreover, both NSAIDs and COXIBs can display side effects on kidney, bringing 
to fluid retention and consequently to increased blood pressure [Hao CM. et al., 2008] or hazard 
could depend upon differences in the levels of lipid peroxides or in the supply of AA substrate 
between platelets and endothelial cells [Mitchell JA. et al., 2006]. Another report suggests that 
the CV toxicity of rofecoxib could be due to its intrinsic physical-chemical properties and 
primary metabolism that increase Low Density Lipoproteins and membrane lipids oxidation thus 
promoting formation of isoprostanes, a characteristic feature of atherogenesis [Mason RP. et al., 
2007 ; Shapiro MS., 2009]. As a result, the CV events may not be ascribed to a class of drugs, 
but rather to distinctive characteristics of each single molecule, including its pharmacokinetic, 
that might affect differently the intricate inter-eicosanoid network of biosynthetic and signaling 
pathways leading to multiple events that may synergize or be functionally opposed, as it is the 
case for platelet function [Rovati GE. et al., 2010]. In order to overcome this problem, several 
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COXIBs combined with moieties that release nitric oxide, an inhibitor of platelet aggregation, 
were developed [Wallace JL. et al., 2009]. But we believe this is not the best approach to solve 
these concerns, due to isoprostanes (like 8-iso-PGF2α or 8-iso-PGE2) and TXA2 implication in 
CV events [Rovati GE. et al., 2010]. The involvement of isoprostanes is of particular interest 
considering that they are nonenzymatic products of fatty acid oxidation, therefore insensitive to 
the action of aspirin and NSAIDs, they are chemically stable and are produced in vivo in 
quantities exceeding those of TxA2 and, finally act through the TxA2 prostanoid (TP) receptor 
[Audoly LP et al., 2000]. 
The Selg et. al study marked a turning point in the NSAIDs saga. In this study it was found that 
diclofenac and lumiracoxib displayed a new mechanism of action, the competitive antagonism of 
the TXA2 receptor (TP) [Selg E. et al., 2007], initially shown using guinea-pig lung strips, and 
later on, with receptor binding experiments in human platelets. But, the main issue that spoils 
this finding was the balance between two activities; the low potency as TP receptor antagonist 
does not permit to exploit this characteristic in therapy [Selg E. et al., 2007].  
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1.4 Cysteinyl Leukotrienes and their receptors 
Cysteinyl-LTs (LTC4, LTD4, and LTE4) are important mediators of asthma and have a 
significant role in the earliest stages of bronchoconstriction, as well as in the late chronic 
inflammatory component [Nicosia S. et al., 2001]. They increase the endothelial cell 
permeability [Capra V. et al., 2015] and are also involved in the leukocyte recruitment and 
activation as well as other inflammatory situations, as immune disorders, CV diseases, several 
cancers, atopic dermatitis, or even GI and hepatic problem as cholestasis, portal hypertension 
[Capra V., 2004][Rovati GE. and Capra V., 2007; Capra V., 2007 ]. In addition cysteinyl-LTs 
are produced in the liver during reperfusion and may enhance cytotoxicity [Takamatsu Y. et al., 
2004]. 
 
LTs receptors belong to the rhodopsin family of the G-protein-coupled receptors (GPCR) and are 
classified in BLT and CysLT receptors based on the ligand, leukotriene B4 (LTB4) and cysteinyl-
LTs [Ba¨ck M. et al., 2011], respectively. Two subtypes of the human Cys-LT receptor have 
been cloned known as CysLT1R and CysLT2R, sharing 38% amino acid identity [Capra V., 
2007][Back M. et al., 2011]. 
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New recent data suggest the existence of supplementary leukotriene receptor subtypes, which 
respond to both, cysteinyl-LTs and uracil nucleosides [Rovati GE. and Capra V. 2007; Austen 
KF. et al., 2009; Back M. et al., 2014]. It is also hypothesized that CysLTRs can form homo or 
heterodimers [Capra V. et al., 2005; Jiang Y. et al., 2007], or that can cross talk with other 
receptors of the membrane [Capra V. et al., 2005][Rovati GE. and Capra V., 2007]. CysLTRs 
may also be localized at the nuclear level, influencing cell function and signaling [Bandeira-
Melo C. et al., (2002b)], therefore be a potential target for a new pharmacological treatment 
[Dalrymple MB. et al., 2008; Kenakin T., 2002].  
 
There is a wide distribution in the human tissues of the CysLTRs, particularly CysLT1 in cells 
with a significant implication in asthma, such as smooth muscle cells along the respiratory tract 
[Figueroa DJ. et al., 2001], monocytes/macrophages, neutrophils, or in tumors like colorectal 
carcinomas, but also in the human mast cells of non asthmatic patients [Ohd JF. et al., 2003; 
Yoshisue H. et al., 2007]. 
Whereas CysLT2 receptor is widely expressed in the brain like thalamus, hypothalamus, and 
medulla [Heise CE. et al., 2000]; in heart, adrenals, basophils [Gauvreau G.M. et al., 2005; 
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Rovati GE. and Capra V., 2007]. Interestingly, CysLT2 receptor are not expressed in cells 
containing high levels of CysLT1 receptor, like both undifferentiated or differentiated 
promyelocytic HL-60 and promonocytic U937 cells [Murray J. et al., 2003; Ba¨ ck M. et al., 
2011]. Cys-LTRs, as well as cysteinyl-LTs, can be also expressed and synthesized, respectively, 
at the atherosclerotic site. 
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1.5  Cysteinlyl-leukotriene receptor antagonists, montelukast 
Asthma is a very common based inflammatory pathology, in both adults and children, 
characterized by airway reversible alterations. The pharmacological control of patients having 
asthma is based on the administration of a bronchodilator, which should be combined also with 
an anti-inflammatory drug, like corticosteroids, in order to prevent chronic inflammation. Based 
on the fact that cysteinyl-LTs play a crucial role in asthma, the CysLTR antagonists drugs 
(LTRAs) are used since the late 1990s as an alternative therapy in patients having asthma, and 
later on, also in other inflammatory conditions as chronic obstructive pulmonary disease (COPD) 
or allergic rhinitis and urticaria [Capra V. et al., 2006]. At the same time, few studies have 
reported that some patients taking a LTRA do not respond to the treatment [Drazen JM. et al., 
1999; Israel E., 2005], which suggest that in some asthmatics, the symptoms are due to other 
mediators than cysteinyl-LTs, therefore indentifying a particular phenotype resistant to LTRAs 
[Asano K. et al., 2002; Tantisira KG. et al., 2009; Langmack EL. and Martin RJ., 2010] is of 
particular interest. 
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Several studies have indicated that LTRA can also decrease the intimal hyperplasia following 
vascular injury, as well as can prevent the atherosclerosis progression, and have a protective role 
after cerebral ischemia [Riccioni G. et al., 2008][Bäck M., 2009][Capra V. et al., 2013].  
Patients having COPD are characterized by chronic pulmonary inflammation which is different 
than in asthmatic patients. Evidences have shown increased levels of PGE2 in COPD, and 
increased levels of LTE4 in asthma [Montuschi P. et al., 2003; Gaki E. et al., 2007]. However, 
zafirlukast seems to improve the lung function in smoker with COPD [Cazzola M. et al., 2000; 
Nannini LJ. and Flores DM., 2003], but, on the other hand, due to relevant neutrophilic 
inflammation in COPD, LTB4 may have a role in this disease, hence, taking a BLT antagonist or 
5-LO/FLAP inhibitor can be a better pharmacological approach in these patients.   
Allergic rhinitis (AR) is one of the diseases that may be target by LTRAs. Cysteinyl-LTs are 
produced in some of the cells responsible for AR, and CysLTRs are also involved in its 
pathology [Peters-Golden M. and Henderson WR Jr., 2005; Peters-Golden M. et al., 2006]. At 
the same time some studies indicate a possible role of cysteinyl-LTs and their receptors in 
chronic rhinosinusitis [Arango P. et al., 2002; Higashi N. et al., 2004; Sousa AR. et al., 2002], so 
LTRA can be a potential therapeutic alternative in this disease. 
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Atopic dermatitis (AD) and chronic urticaria are two pathologies that can as well be treated with 
LTRAs. Increased levels of urinary LTE4 were detected in patients with AD [Adamek-Guzik T. 
et al., 2002; Øymar K. and Aksnes L., 2005], and LTRAs taken at the same doses as for asthma 
treatment have shown a symptomatology improvement, in both adult and children with different 
stages of AD, even though some controversial studies have been published [Veien NK. et al., 
2005, Capra V. et al., 2006; Leonardi S. et al., 2007; Broshtilova V. and Gantcheva M., 2010].   
 
Other diseases like cystic fibrosis are characterized by increased levels of cysteinyl-LTs due to 
the inflammatory process responsible of lung damage [Reid DW. et al., 2007], and LTRAs have 
shown to improve cystic fibrosis especially in the long-term [Schmitt-Grohe´ S. et al., 2007].  
 
Several antagonists of the CysLTRs, i.e. pranlukast, zafirlukast, montelukast, and pobilukast, 
were designed as selective CysLT1R antagonists [Brink C. et al., 2003; Evans JF., 2003; Capra 
V., 2004]. At variance, BAY u9773, differs from the other compounds by acting as an antagonist 
of both CysLT1 and CysLT2 receptors, even if with poor potency and selectivity [Labat C. et al., 
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1992; Tudhope S.R. et al., 1994]. Generally speaking, the first generation of CysLTR antagonists 
did not demonstrate sufficient potency for endogenous ligands [Ba¨ ck. M, et al., 2011]. 
 
Montelukast, a potent antagonist of the CysLT1R subtype is used in patients having different 
stages of asthma severity. Furthermore, montelukast, as well as other LTRAs like zafirlukast or 
pranlukast can be used in AR. Montelukast can be used in children [Bisgaard H. et al., 2009], 
and to alleviate the symptoms present in AR, like eye and throat symptoms [Grainger J. and 
Drake-Lee A., 2006; Nayak A. and Langdon RB., 2007; Bousquet J. et al., 2009] as a 
monotherapy or in association with other antihistamic drugs [Meltzer EO. et al., 2000; Nayak 
AS. et al., 2002]. Montelukast was approved by the Food and Drug Administration (FDA) in 
2003 for the treatment of seasonal AR and in 2005 for the treatment of perennial AR [Ba¨ ck. M. 
et al., 2011].  
The Rubeinstein group studied the functional scores of COPD patients taking montelukast, and 
came to the conclusion that there was an improvement of nocturnal symptoms, (shortness of 
breath, wheezing, use of other drugs, as inhaled bronchodilators, corticosteroids, the number and 
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duration of hospitalizations, and emergency visits [Rubinstein I. et al., 2004; Celik P. et al., 
2005]. 
 
In addition to these uses, montelukast is a choice in patients that do not respond to antihistaminic 
therapy [Erbagci Z., 2002; Bagenstose SE. et al., 2004]. 
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1.6  Inflammation and cardiovascular events  
Inflammation is a physiological reaction, triggered by a number of agents, involving, both blood 
cells (macrophages, monocytes), and vessel wall (vascular endothelium), characterized by the 
release of chemical mediators, and associated with the elimination of the invading host after 
identification. Increase in vascular permeability, leukocyte infiltration (consisting in margination, 
rolling, adhesion and diapedesis) in the injured district are some of the features of edema. 
Initially, prostaglandins, LTs, and other inflammatory mediators such as histamine, serotonine, 
nitrogen oxide, and bradykinin are released, while successively the migration of leukocytes and 
intensification of the inflammatory response dominates, and eventually failure of organ functions 
and tissues repair induced by proliferation of connective tissue, particularly fibroblasts.  IL-1 and 
TNF are two main inflammatory mediators, which enhance the synthesis of several proteins and 
the activation of neutrophils, cytokines, COX, LOX, B and T lymphocytes. 
Inflammation is associated to several diseases, like atherosclerosis or asthma [Inglesson E. et al., 
2012], highlighting the fact that CV events are among the most common cause of death 
worldwide. Endogenous ligands can be present at the inflammatory and myocardial damage site.   
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Even though several NSAIDs have been designed and commercialized, all of them can increase 
the CV risk. The development of COXIBs seemed to be an exalting invention in the NSAIDs 
field, but the triumph did not last longer, as Vioxx was withdrawn and followed by other 
frustrations due to CV toxicity associated to COXIB and traditional NSAIDs, including 
paracetamol [Ritter JM. et al., 2009].   
 
At the same time, other AA metabolite, such as LTs, are associated to inflammation [Samuelsson 
B., 1983] and can enhance the CV risk.  
 
LTs are part of the inflammatory process of several pathologies including CV diseases 
characterized by the increase of capillary permeability, vasoconstrictor properties, reduction of 
coronary blood flow [Capra V. et al., 2007, Brink C. et al., 2003]. MI, stroke, atherosclerosis, 
aortic aneurysms are some of the CV events characterized by generation of LTs from 5-LO 
pathway, a substantial part of vascular inflammation and disease progression [Lo¨tzer K. et al., 
2005; Ba¨ ck M., 2009, Ba¨ck M. et al., 2007]. Several controversial studies claim the role of 
cysteinyl-LTs in the amplification of myocardial ischemic injury [Toki Y. et al., 1988; Hock CE. 
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et al., 1992], eventhough challenged by others studies, which claim their marginal or no role in 
ischemic and myocardial dysfunction [Ito T. et al., 1989; Hahn RA. et al., 1992]. Interestingly 
both CysLT receptors are found in injured human arteries [Allen S. et al., 1998; Spanbroek R. et 
al., 2003]. Given their association with the inflammatory onset and amplification, LTs synthesis 
inhibitors or LTRAs can be consider as potential approach for CV diseases. In addition, in vivo 
mouse data’s revealed the effect of montelukast in reducing the vascular reactive oxygen species 
production, improving endothelial cells function [Mueller CF. et al., 2008], inhibiting 
atherosclerotic damaged area and intimal hyperplasia [Kaetsu Y. et al., 2007; Jawien J. et al., 
2008], improving atherosclerotic plaque generation [Mueller CF. et al., 2008]. Moreover, 
Allayee group revealed an important reduction of C-reactive protein in asthmatic patients treated 
with montelukast [Allayee H. et al., 2007]. Montelukast can inhibit the MCP-1, and is 
responsible for the antiatherogenic effects in vivo in the rabbit carotid injury model [Ge S. et al., 
2009], while it has been demonstrated to be useful in preventing hepatic ischemia-reperfusion 
injury in rats [Daglar G. et al., 2009]. 
Whereas, CysLT2R are principally present in brain and selective CysLT2R antagonists can be 
used to reduce the blood permeability in the brain [Capra V. et al., 2015; Di Gennaro A. et al., 
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2004], hence cerebral ischemia [Biber N. et al., 2009; Yu GL. et al., 2005a,b; Qian XD. et al., 
2006]. In a different perspective the overexpression of CysLT2R in mice, can intensify the 
myocardial ischemia-reperfusion damage [Hui Y. et al., 2004]. Yet, BAY U9773, a 
CysLT1/CysLT2 receptor antagonist is more effective than other CysLT1R antagonist in 
preventing the changes in brain permeability [Di Gennaro A. et al., 2004]. Allen group sustained 
that cysteinyl-LTs enhanced human atherosclerotic coronary arteries contractions, but at the 
same time arteries lacking the atherosclerosis plaque were unresponsive [Allen S. et al., 1998]. 
These solid data indicate that CysLT2R is an essential pharmacological target to face the CV 
events.  
 
Therefore, we are currently exploring two potential alternatives to approach and reduce the CV 
risk in inflammatory diseases: 
1) to use a LTRAs, which has already been demonstrated to prevent the inflammatory response 
present in pathologies like asthma, AR, AD or chronic urticaria, and that might be considered as 
a new therapeutic approach in several other inflammatory diseases including carotid and 
coronary atherosclerosis to improve their CV outcome; 
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2) to use a multitarget drug possessing a dual COXIB and TP antagonist activity within a single 
molecule to reduce inflammation, and to inhibit TP receptor activation, including that from 
isoprostanes, which are known to be generated during atherogenesis and that cannot be prevented 
using a traditional NSAID or a COXIB. 
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II- AIM OF THE STUDY 
Approaching the CV issues is a delicate matter, and the aim of our study was to propose 
alternative solutions targeting the specific AA metabolites for reducing the CV risk in patients 
suffering from inflammatory disease, like rheumatoid arthritis or asthma. 
The first aim of our study was the design and the pharmacological characterization of new 
compounds possessing the anti-inflammatory and TP antagonist activity within a single 
compound [Bertinaria M. et al., 2012]. New molecules were synthesized at the University of 
Turin, starting from a COXIB, i.e. lumiracoxib, modifying its structure to increase TP antagonist 
potency and introducing some functional groups of the TP antagonist terutroban, in order to 
combine these two activities in a multitarget drug. Lumiracoxib and naproxene were used as 
reference drugs and their anti-aggregating activity was assessed in both human platelets 
stimulated by U46619, a specific stable agonist of the TP receptor, and in HEK293 cells 
transfected with the TPα receptor in terms of inhibition of inositol phosphate production. COX-1 
and COX-2 activity were studied in washed platelets and human monocytes, respectively. By 
developing these dual compounds we can speculate not only to give rise to a new generation of 
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NSAID with reduced GI and CV side-effects, but also to achieve a novelty in terms of 
preventing the interaction of isoprostanes with the TP receptor.  
 
The second aim of our study was to perform an observational retrospective study to determine 
whether there is a protective role of the LTRA drug montelukast in the prevention of a major CV 
events (i.e. stroke or MI) in subjects exposed to the drug for a different pathology. As discussed 
above, montelukast is a pharmacological alternative for patients suffering from asthma or AR. 
Asthmatic patients exposed or non exposed to montelukast participated in the study, and they 
were further classified in subject with or without prior CV events such as ischemic stroke (IS) or 
MI. Data were collected regarding patients details, as well as the drugs use, age, income, 
residence, education level, and were analysed to determine whether or not there was a correlation 
between montelukast and the primary or secondary prevention of a major CV event.  
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III- MATERIALS AND METHODS 
PROJECT I METHODS 
3.1 Materials 
U46619 ([1R-[1,4,5(Z),6(1E,3S*)]]-7-[6-(3-hydroxy-1-octenyl)-2-oxabicyclo[2.2.1]hept-
5-yl]- 5-heptenoic acid), and SQ29,548 ([1S-[1,2(Z),3,4]]-7-[3-[[2-
[(phenylamino)carbonyl]-hydrazino]methyl]-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid) 
were purchased from Cayman Chemical (Ann Arbor, MI).  
Ultima Gold  and myo-[2-
3
H]inositol were obtained from PerkinElmer Life and Analytical 
Sciences (Boston, MA). 
Lowry dye-binding protein reagents and anion exchange resin AG 1X-8 (formate form, 200–400 
mesh) were purchased from Bio-Rad (Hercules, CA).  
Antibiotics, Lipofectamine 2000, animal serum, molecular biology reagents and Opti-MEM I 
were bought from Invitrogen (Carlsbad, CA).  
Inositol-free Dulbecco’s modified Eagle’s medium (DMEM) was acquired from ICN 
Pharmaceuticals Inc. (Costa Mesa, CA).  
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Highest purity reagents were supplied by Sigma-Aldrich (St. Louis, MO). 
DMEM MP Biomedicals, was procured from Santa Ana, CA. 
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3.2 Human platelets isolation and platelet aggregation   
Platelets were isolated from human blood of healthy volunteers (18-60 years old) lacking any CV 
disease, and not taking medications for at least 72 h. An anticoagulant, respectively, CPD 
solution (Citrate Phosphate Dextrose; sodium citrate, dihydrate, 26.3 g/L; dextrose, 
monohydrate, 25.5 g/L; citric acid, anhydrous 3.27 g/L; monobasic sodium phosphate, 
monohydrate, 2.22 g/L) was added to the blood. Platelet-rich plasma (PRP), was obtained after 
centrifugation of buffy coat treated with 100 μM of acetylsalicylic acid at 280 g for 15 min at 
room temperature, and immediately afterwards at 650 g for 10 min at room temperature. 8 ml of 
washing buffer (mM composition: citric acid monohydrate 39, glucose monohydrate 5, KCl 5, 
CaCl2 2, MgCl2 x 6H2O 1, NaCl 103, pH 6.5), was used to suspend the platelet pellet. 
Furthermore the platelet pellet was centrifuged at 650 g for 15 min at room temperature and 
resuspended in 15 ml of HBSS (Hank’s Balance Salt Solution: CaCl2·2H2O 0.185 g/L; KCl 0.40 
g/L; KH2PO4 0.06 g/L; MgCl2·6H2O 0.10 g/L; MgSO4·7H2O 0.10 g/L; NaCl 8.00 g/L; NaHCO3 
0.35 g/L; Na2HPO4 0.048 g/L; D-glucose 1.00 g/L). Platelet aggregation was evaluated using a 
Chrono-Log aggregometer (Mascia Brunelli, Milano, Italy), after settling the washed platelets 
concentration at almost 2 x10
8
 cell ml
-1
 and applying the Born turbidimetric assay [Born GV. and 
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Cross MJ., 1963] at 37°C in a 0.5 mL sample.The platelet were incubated with drug or vehicle 
(DMSO, maximum 0.2 %, v:v) for 5 min at 37°C, and induced by the specific TP receptor 
agonist, U46619 (0.1-0.5 μM) under continuous stirring for 6 minutes. Due to different platelet 
response, the anti-aggregating activity of each compound was compared with its respective 
control aggregation.  
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3.3 Isolation of lympho-monocytes, COX-2 expression and study of COX-2 inhibitory  
activity 
 
 
 
 Buffy coat obtained from healthy volunteers were used as a source of isolation of lympho-
monocytes, by a Ficoll-Paque gradient density centrifugation (400 g for 30 min at 10°C), 
following dilution in a saline solution (NaCl 0.9%) and ricentrifugation (280 g for 15 min at 
10°C). After the remaining suspended platelets were removed, in order to eliminate the 
remaining erythrocytes the lysis buffer (NaCl 0.2% weight/volume, w/v) was added and 
balanced with an equal volume of equilibrating solution (NaCl 1.6% + saccarose 0.2%, w/v). 
Lympho-monocytes were resuspended in HBSS and COX-2 inhibition assays were carried out.  
In order to avoid potential binding of the respective compounds with plasma proteins, COXIB 
activity was assessed in isolated human lympho-monocytes after treatment with 10 µg/mL of 
acetylsalicylic acid. Lipopolysaccharide (LPS) (from E. coli, serotype 0111:B4; 10 μg ml-1) was 
used as a physiological inducer of the expression of COX-2 isoform. The samples were 
incubated overnight at 37°C  and COX-2 activity was assessed through the Prostaglandin E2 
(PGE2) production by mass spectrometry or enzyme immunoassay (PGE2  EIA kit, Cayman 
Chemical). When the incubation phase was completed, the samples were centrifuged at 12000 g 
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for 2 minutes. The evaluation of PGE2 content was carried out using the isolated supernatant 
freezed at -20°C.  IC50 of the compounds  was calculated versus the maximal PGE2 production. 
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3.4 COX-1 inhibitory activity  
COX-1 inhibitory activity of the tested compounds was assessed in washed human platelets 
suspension. Cells concentration was settled at 2 x 10
8
 cells ml
-1
. Increasing concentrations of the 
tested compounds, were used to treat platelets for 15 min, and thereafter incubated at 37°C in a 
Dubnoff bath. TXB2 was used as a marker of activity of COX-1, and its production by platelet 
degranulation was enhanced by calcium ionophore (A23187 2μM). The samples were 
centrifuged at 5000g for 5min at 4°C, following an incubation period of 10 min at 37°C. TXB2 
production was assessed in the supernatant through immunoenzymatic assay of TXB2 production 
and mass spectroscopy.  
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3.5 Mass spectrometry 
Liquid chromatography-tandem mass spectrometry was used to determine PGE2 and TxB2 
concentrations, making use of the deuterated internal standards [d4] PGE2 and [d4] TxB2. 
Internal standards was added to the samples and injected in a liquid chromatography Agilent 
1100 (Agilent Technologies, Santa Clara, CA). A reverse phase column (Synergi 4 μm Hydro-
RP, 150x2 mm; Phenomenex, Torrance, CA) was used and the column was eluted with a 
gradient, made of 25 to 100% of solvent B (Methanol:Acetonitrile, 65:35) for 10 min and of 
Solvent A, consisting in 0.05% acetic acid pH 6 with ammonia. The current transition m/z 
351>271 for PGE2, m/z 355>275 for [d4] PGE2, m/z 369>169 for TXB2 and m/z 373>173 for 
[d4] TXB2 were monitored after infusion of the effluent in an API4000 triple quadrupole 
operated in negative ion mode. Standard curves obtained from different standards (Cayman 
Chemical, Ann Arbor, MI) were used for quantization. 
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3.6 Culture and transfection of HEK293 cells  
Human embryonic kidney cell line (HEK293) cells (ATCC, Manassas, VA) were cultured in 
Dulbecco’s modified Eagle’s medium (DMEM) containing 10% of fetal bovine serum (FBS), 2 
mM glutamine, 50 U mL-1 penicillin, 100 μg mL-1 streptomycin, and 20 mM HEPES buffer, pH 
7.4, at 37°C in a humidified atmosphere of 95% air and 5% CO2. 12-well dishes, precoated with 
poly-D-lysine, were used to plate the cells, to ensure that at the time of transfection the 
confluence will be around 50–60%. HEK 293 cells were transfected with the TPα WT receptor, 
using the transfectant agent, Lipofectamine2000 (Invitrogen, Carlsbad, CA) according to the 
manufacturer’s instructions, in an Opti-MEM I Medium with a 2:1 ratio, which was added to the 
cells after 20 min incubation at room temperature. Lowry dye binding procedure was used to 
confirm equal protein content for each respective analysis.  
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3.7 Total inositol phosphate determination in HEK293 cells  
HEK293 cells transfected with the TPα WT receptor were labeled the day prior to the assay, with 
0.5-1 µCi/ml of myo-[2-3H]inositol (PerkinElmer Life and Analytical Sciences, Boston, MA) for 
24 h in DMEM (MP Biomedicals, Santa Ana, CA), free of inositol and serum, containing 20 mM 
HEPES buffer pH 7.4,  0.5% (w:v) Albumax, 2 mM glutamine, and 100U/ml penicillin-
streptomycine. 48 h after transfection with the TPα WT receptor, its functional activity was 
evaluated through a column ion exchange chromatography by total labeled inositol phosphates 
production. 25 mM of  LiCl were used to incubate the cells for 10 min at the day of the assay, 
accompanied with a pretreatment for 30 min at 37°C with the antagonist, and than stimulated 
with the specific agonist of TP receptor, compound U46619 0.1µM. Cells were lysed with 10 
mM of formic acid for 30 min at 4°C, stopping the reaction and transferring the acidic phase in 5 
mM NH4OH pH 8-9. Extraction of the total inositol phosphate production is accomplished by 
chromatography AG 1X-8 columns formate form, 200–400 mesh size (BioRad Laboratories, 
Hercules, CA). 
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3.8 Statistical analysis I 
Prism 5 (GraphPad Software Inc., San Diego, CA) was used to calculate the pA2 values based on 
the following equations:  
1) Agonist response = Bottom + (Top-Bottom)/(1+10^((LogEC50-X)*HillSlope)) 
2) Antagonist response = Bottom+(Top-Bottom)/(1+(Antag/FixedAg)^HillSlope) 
3) Antag = (10^LogEC50)*(1+((10^X)/(10^(-1*pA2)))^SchildSlope) 
Hill Slope is the slope of the curves, X indicate the Log concentration of the agonist, Bottom is 
the response when X = 0, Top is the response for an infinite concentration of X, EC50 is the 
concentration of the agonist that induce half of the response, FixedAg is the initial fixed 
concentration of the agonist used to determine the antagonist inhibition curve.  
 
The four-parameter logistic models were used to analyze the concentration-response curves of 
platelet aggregation and the parameter errors calculated by simultaneous analysis of at least three 
different independent experiments carried out in duplicate or triplicate, were expressed in 
percentage coefficient of variation (% CV). A value of P<0.05 was used as the statistical level of 
significance.  
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PROJECT II METHODS 
3.9  Data collection 
Data from 18 years or older asthmatic patients were collected from different allergist/pathologist 
around the country based on patient medical records, patient register and the drug used. 
Asthmatic patients were divided in two samples the first one, patients taking montelukast and the 
second sample consisting of asthmatic patients not taking montelukast. The sample size was 400 
patients for each of two groups. The study was retrospective and the exposure to montelukast 
was considered to be at least 3 months of continual use of montelukast [Ingelsson E. et.al., 
2012]. Each of the two subjects sample was further classified in patients with or without MI or IS 
based on their diagnosis according to the International Classification of Diseases (ICD). The 
drugs used for CV diseases were retained to be very important factor of monitoring in both two 
samples, in order to avoid a pre-predisposure of the monitored patients to an increased CV risk 
for MI and stroke. From the other hand educational level, categorized as low (elementary and 
primary school 0-9
th
 grade), medium (high school 10
th
-12
th
 grade) and high (university studies) 
was evaluated together with the patients economic status, yearly income. 
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4.0 Statistical analysis II 
 
R statistical software was used for the statistical analysis. Fisher’s exact test was used to 
calculate and assess the difference from the null hypothesis, i.e. whether the treatment with 
montelukast affects or not the outcome, the MI or IS events. 2 x 2 contigency table was used 
both for myocardial events and IS events.  
 Myocardial 
infaction/ischemic 
stroke events 
Absence of 
myocardial 
infarction/ischemic 
stroke events 
Raw total 
Treatment with 
montelukast 
a b a+b 
No treatment with 
montelukast 
c d c+d 
Column total a+c b+d a+b+c+d (=n) 
 
  
n is the grand total and is equal to the sum of all total across columns and raws. Hypergeometric 
distribution was used to calculate the p value, in order to evaluate if the null hypothesis is 
accepted or rejected.  
The null hypothesis implies that the two variables hence treatment or not with montelukast and 
presence or absence of MI/IS are independent from each other.  
The p-value is calculated as follows: 
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! corresponds to the factorial operator  
  corresponds to the binomial coefficient 
 
The p value obtained from our data was compared to the significance level fixed at 5%; if the p 
value was inferior to 5% the null hypothesis was rejected and vice versa. 
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IV- RESULTS 
 
PROJECT I RESULTS 
A number of compounds were synthesized at the University of Turin, from which the most 
interesting, resulted to be the compound 7, 18, 20 and 32 (Fig 3). Naproxene and lumiracoxib, a 
derivative of diclofenac were used as reference compounds, whereas terutroban sulfonyl 
functional group was inserted in the new synthesized compound, i.e. compound 20.  
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Fig 3. Chemical structures of new synthesized compound, 7, 18, 20, 32 and of terutroban and the 
reference compounds naproxen, lumiracoxib, diclofenac 
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4.1 Chemical Synthesis 
For the synthesis of compounds 7 and 32 the procedure reported in Figure 4 was used. Chan-
Lam coupling was applied for the synthesis of compound 7, a lumiracoxib analogue, by the 
reaction of 2-amino-5-methylbenzoic acid with 2-chloro-6-fluorophenylboronic acid in the 
presence of 1,8-diazabicylo-[5,4,0]undec-7-ene (DBU) and a stoichiometric amount of copper 
acetate in dioxane solution. Compound 32 was synthesized by reacting 2-amino-5-methylbenzoic 
acid with 4-chlorobenzensulfonyl chloride in the presence of excess Na2CO3 in water at 60 – 80 
°C. The product was isolated and recrystallized from ethanol.  
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Fig 4. Chemical synthesis of compound 7 and 32 
 
Compound 18, the tetrazole derivative, as well as compound 20 were obtained from a nitrile 
derivative. The latter reduction with THF complex in refluxing THF and subsequent 
sulfonylation in basic medium, using trifluoromethanesulfonic anhydride, gave rise to the 
sulfonamide compound 20 (N- [2-[2-[(2- chloro-6-fluorophenil) ammino]-5- methylphenyl] 
ethyl]- 1,1,1-trifluoromethansulfonamide) (Fig 5). The precursor nitrile derivative was treated 
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with excess NaN3 and NH4Cl in DMF at 120°C, which brought to the cyclization of the tetrazole 
isoster 18 (N-(2-chloro-6-fluorophenyl)-4- methyl-2-(1H-tetrazol-5-ylmethyl)-benzenamine) 
(Fig 5). 
 
 
Fig 5. Chemical synthesis of compound 18 and 20 
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4.2 Antagonism of TPα functional activity in human platelets 
 
 
Inhibition of TP receptor functional activity by the new synthesized compounds, as well as by 
the reference compounds, like, naproxen, lumiracoxib, diclofenac was assessed in human 
platelets from healthy volunteers. The platelet aggregation was studied through Born-
turbidimetric assay. 100 μM of acetylsalicylic acid was added to the blood to make platelets 
become unresponsive to AA stimulation (1-3 μM), but responsive to the calcium ionophore A-
23187 (3 μM). Representative traces of platelet aggregation obtained from the stimulation with 
0.1 µM of U46619, and increasing concentrations (0.3-20 μM) of compounds 18 and 20 are 
reported in Figure 6. When washed platelets were challenged with increasing concentrations of 
the stable TxA2 analogue U46619 a concentration-dependent platelet aggregation occurred with 
a potency of 59 nM ±19 % CV (Figure 7). This response was thus truly independent of 
endogenous TxA2 formation. The inhibition curves of U46619-induced (0.1 µM) platelet 
aggregation in the presence of increasing concentrations of the tested compounds as well as the 
reference compounds are also reported in Figure 7. pA2 values of the tested compounds were 
calculated (as described in method section) and reported in Table 1. Among all the tested 
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compounds, compound 18 and 20 resulted to be the most potent as TP antagonist, showing 
similar data as for diclofenac, while compound 20 displayed a pA2 value statistically different 
form lumiracoxib (pA2 = 5.9, 95% CI - Confidence Interval 5.5-6.4 for cp 20 - pA2 = 5.1, 95% 
CI - Confidence Interval 4.8-5.4 for lumiracoxib) (Fig 7).  
 
 
 
 
 
 
Figure 6. Platelet aggregation traces recovered from the stimulation with 0.1 µM of U46619, and 
increasing concentrations (0.3-20 μM) of compounds 18 and 20 
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Compound 
 
pA2 ± %CV 
Human washed platelet 
aggregation 
Total IP production in 
HEK293 cells 
Lumiracoxib 5.1 ± 3.4 4.6 ± 5.9 
Diclofenac 5.4 ± 4.9 5.3 ± 4.7 
Naproxen 4.1 ± 2.5 3.9 ± 16.3 
Terutroban 9.4 ± 4.1 9.3 ± 2.8 
18 5.6 ± 3.5 5.5*± 2.2 
20 5.9* ± 4.1 5.7* ± 2.3 
7 5.0 ± 1.8 4.9 ± 5.1 
32 4.8 ± 2.4 4.8 ± 2.5 
                                         * 95% CI vs. lumiracoxib 
 
 
 
Table 1. TP receptor antagonism at human washed platelet aggregation and total IP production 
in transfected HEK 293 cells. pA2 values were determined by measuring inhibition of 
aggregation response to the stable agonist U46619 
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Figure 7. pA2 values of the tested compounds determined by measuring inhibition of 
aggregation response to the stable agonist U46619 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
53 
 
 
 
4.3 Antagonism of TPα functional activity in HEK293 transfected cells 
 
 
HEK293 cells were transfected with the TPα receptor and the ability of the compounds to inhibit 
the total inositol phosphate (IP) production due to TP receptor coupling with Gq was assessed by 
stimulating cells with the specific receptor agonist U46619 (0.1 μM, 30min), in the absence and 
presence of 30 min pretreatment with increasing concentrations of the reported compounds. The 
EC50 calculated after the stimulation of TPα with U46619 was 29.3 nM ± 10 % CV (Fig. 8). 
 
The pA2 values of the compounds calculated in HEK 293 cells similarly to human platelet 
aggregation are reported in Table 1. It is important to highlight that pA2 values calculated for 
each compound in HEK 293 transfected cells are in full agreement with the results obtained in 
the aggregation assay. Once again, compounds 18 and 20 resulted to be the most potent 
compounds of the series, displaying pA2 values similar to diclofenac (Fig. 8), but statistically 
different from lumiracoxib (pA2 = 5.5, 95% CI, 5.2-5.8 for cp 18 - pA2 = 5.7, 95% CI, 5.4-6.0 for 
cp 20 - pA2 = 4.6 95% CI, 4.1-5.1 for lumiracoxib), matching the affinity binding data obtained 
in HEK293 cells [Bertinaria M. et al., 2012]. 
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Figure 8. pA2 values of the tested compounds obtained in total IP production inhibition in 
HEK293 cells transfected with TPα receptor 
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4.4 Evaluation of COX-2/COX-1 selectivity 
 
The ability of the compounds to act as COX-2 inhibitors was determined in isolated human 
lympho-monocytes. All the new compounds should preserve a COX-2 selectivity similar to 
lumiracoxib, their reference compound. After treatment with acetylsalicylic acid, 10 μg/mL of 
lipopolysaccharide overnight was added to stimulate COX-2 expression, hence PGE2 production, 
a marker of COX-2 activity, was determined by enzyme immunoassay and mass spectrometry. 
 
Among all the tested compounds diclofenac and lumiracoxib possessed the highest absolute 
potency (Table 2) for inhibiting the COX-2 in a concentration-dependent manner, whereas 
compound 32, a derivative of TP receptor antagonist terutroban maintaining the 4-
chlorobenzensulfonamide moiety present in terutroban, resulted to be the less potent molecule 
(Table 2) of the series. Both compound 18, a tetrazole derivative, and compound 7 behaved very 
similarly, by inhibiting COX-2 with potencies of 0.014 and 0.025 µM, respectively, whereas 
compound 20 displayed a potency similar to naproxen (Figure 9 and Table 2).  
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On the other hand COX-1 inhibitory activity, assessed in washed human platelets as TXB2 
production, was determined by mass spectrometry. Out of all the tested compounds, diclofenac 
displayed the highest potency as COX-1 inhibitor in washed platelets, falling in the nM range, 
followed by naproxen (Table 2). In fully agreement with COX-2 inhibitory activity, the  
tetrazole derivative 18 and compound 7, behaved very similarly with IC50 values of 13.2 μM and 
25.5 μM, respectively, whereas, differently, the sulfonamide derivative 20 showed an IC50 of 
16.1 µM, close to that of compound 18 and 7. Compound 32, was inactive as COX-1 inhibitor 
(Figure 9 and Table 2). 
 
The selectivity profile of all the tested compounds is reported in Figure 9, showing that naproxen 
and lumiracoxib were respectively, the less and the most selective COX-2 inhibitors (Table 2). 
Among all the newly synthesized compounds, compound 18 and 7 resulted to be the most 
selective COXIBs (Figure 10, Table 2). Eventhough compound 20 is only 38 times more 
selective for COX-2 with respect to COX- 1 inhibition at calculated IC50, it showed a very steep 
concentration-response curve (Hill coefficient >>1). Therefore, at a concentration ten times its 
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IC50 for COX-2 inhibition, about 95% of COX-2 is inhibited, with no inhibition of COX-1 (Fig. 
9c). 
 
 
Table 2. COX-2 and COX-1 inhibitory activities determined by in vitro assay in 
lymphomonocytes and washed human platelets, respectively 
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Figure 9. Inhibition of COX-1 and COX-2 activity by different compounds in comparison to the 
reference compound naproxen (a-d). 
Data are expressed as percent inhibition of TXB2 or PGE2 release versus untreated controls. 
Error bars represent mean ± SE of at least three independent experiments, each performed in 
duplicate. 
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Figure 10. COX-2/COX-1 selectivity. The diagonal line indicates equivalence, hence, 
compounds with high selectivity for COX-2 over COX-1 are plotted beneath the line 
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PROJECT II RESULTS 
 
The summary table containing all the patients characteristics, including mean age, gender, 
residence, educational level, income, and drug prescription is reported in Table 3.                                                                                                                                                                                                             
 
The mean age of patients exposed to montelukast and having a history of MI is 68.50 years old, 
whereas that of patients suffering from MI but not exposed to montelukast is 71.40 years old, 
respectively. Regarding IS the mean age of patients with a history of IS using montelukast is 70 
years old, with respect to 74.22 years old in patient not taking montelukast. The mean age of 
patients, exposed or not to montelukast, without a MI (57.1 and 61.84, respectively) or IS (57.18 
and 62.16, respectively) event is relatively lower than that of patients having a history of CV 
events (as stated above), with at least 9 years difference, suggesting that age can contribute to the 
increase of CV risk, something not completely unexpected. 
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In case when at least one of the contingency table cells is less than five, or for small sample 
sizes, Fisher's Exact test was used to calculate the relationship between two categorical variables; 
otherwise Chi-squared test was implemented.  
In subjects with MI exposed or not to montelukast the number of males was higher than that of 
females (75% males vs 25% females, in subjects using montelukast and 56% males vs 44% 
females in subjects not taking montelukast) whereas, interestingly, the proportion was inverted in 
IS (33% males vs 67% females in subjects unexposed to the drug with a prior IS event; the only 
IS in patients exposed to montelukast was indeed a female). Fisher exact test was used to 
calculate the two way interaction between gender and exposure to montelukast use in subjects 
with MI. The calculated p value was 0.622, so the null hypothesis is accepted and the two 
variables gender and exposure to the drug in subjects with MI are to be considered independent. 
The p-value of the Chi-square statistic test for subjects without prior MI exposed or not to 
montelukast and gender was 0.917, once again, suggesting no correlation between the two 
variables. The p value corresponding to Fisher exact test for gender and exposure to montelukast 
in patients with IS resulted to be less than 5%, which means that there is a correlation between 
the respective variables. Based on the data we obtained, although they are limited, it is possible 
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than females can be more predisposed to IS whether exposed or not to montelukast (1.62 % vs 
0.82% males). Whereas the p value regarding the Chi square test for dependence of gender and 
exposure to the drug in patients without IS resulted to be 0.96, accepting the null hypothesis, 
hence no correlation is seen between two variables. 
 
The data indicated that for both sample size exposed or not to montelukast without a prior CV 
event, such as MI or IS, the majority of subjects were resident in urban areas. 73% of all exposed 
patients are resident in urban areas, while 92% of all unexposed patients are resident in urban 
areas.  
 
Subject samples education level was also studied, showing a 50% mid education level in the 
exposed patient with a prior MI, vs 60% of low education level in unexposed patients with a 
prior MI. Regarding IS events in both samples it was revealed that mid education level was 
predominant, 100% and 56% in exposed and unexposed patients, respectively. Furthermore, in 
subjects without prior CV events whether exposed or not to montelukast, it was evident a 
relatively higher number of mid education patients level. 
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Socioeconomic status was also analysed indicating overall a very low number of events in 
patients with high income in both sample sizes (4% vs 6% in exposed and unexposed patients 
respectively), and close datas between mid and low yearly income (52.25% vs 45% for mid 
education and 43.75% vs 49% for low education in exposed and unexposed patients 
respectively).  
 
The monitoring of the drug used by each of the sample size was essential to exclude potential 
confounders of the results, the predisposure to CV events, hence the use of antihipertensive 
drugs, diuretics, antiplatelet, antihypercolesterolemic, hypoglycemics was very similar in both 
subjects sample, exposed or not to montelukast as shown in Table 3. Regarding the use of 
antihypertensive drugs 49.5% of patients using montelukast take antihypertensive drugs versus 
50.25% of asthmatic non exposed patients. Similar proportions are also maintaned for diuretics 
21% vs 20.75% in exposed and unexposed patients respectively, whereas considering that 
diabetes is also a risk factor for CV diseases and therefore a potential confounder of the results, 
we observed that 5% and 7.25% of exposed and unexposed patients respectively, take 
hypoglicemic drugs.  
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Data recovered indicate that IS is present in 1.25% of our sample, consisting of eight hundred 
asthmatic patients whereas 3.62%  suffered from MI. Considering that asthma can contribute to 
the increase of CV risk, we retain that these percentages are higher in respect to non asthmatic 
population.  
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Table 3. The study sample characteristics, of both unexposed and exposed patients for MI and 
ischemic stroke (IS) 
 
  
Sample A: 
Exposed (400) 
Sample B: 
Unexposed (400) 
Sample A: 
Exposed (400) 
Sample B: 
Unexposed (400) 
With 
MI 
Witho
ut MI 
With 
MI 
Without 
MI 
With 
IS 
Without 
IS 
With 
IS 
Without 
IS 
No. 
4 (1%) 
396 
(99%) 
25 
(6.25
%) 
375 
(93.75
%) 
1 
(0.25
%) 
399 
(99.75
%) 
9 
(2.25
%) 
391 
(97.75
%) 
Mean Age 68,50 57,10 71,40 61,84 70,00 57,18 74,22 62,16 
Female  25% 54% 44% 55% 100% 54% 67% 54% 
Male 75% 46% 56% 45% 0% 46% 33% 46% 
              Residence               
Urban 75% 73% 96% 92% 100% 73% 100% 92% 
Rural 25% 27% 4% 8% 0% 27% 0% 8% 
          Educational Level               
Low 25% 17% 60% 42% 0% 17% 22% 44% 
Mid 50% 64% 28% 49% 100% 64% 56% 47% 
High 25% 19% 12% 9% 0% 19% 22% 9% 
               Income               
Low 25% 44% 48% 49% 0% 44% 67% 49% 
Mid 75% 52% 44% 45% 100% 52% 22% 46% 
High 0% 4% 8% 6% 0% 4% 11% 6% 
            Drug prescriptions               
Antihypertensives 100% 49% 100% 47% 100% 49% 100% 49% 
Antiplatelets 100% 4% 100% 4% 100% 5% 100% 8% 
Diuretics 100% 20% 100% 15% 100% 21% 100% 19% 
Antipsychotics 0% 0% 0% 1% 0% 0% 0% 1% 
Antiandrogens 25% 1% 4% 3% 0% 1% 0% 3% 
Antithyroids 0% 1% 4% 1% 0% 1% 0% 1% 
Antihypercholesterole
mics 100% 14% 100% 13% 
100% 
14% 
100% 17% 
Antihistamines 0% 1% 0% 1% 0% 1% 0% 1% 
Antipeptics 0% 0% 4% 1% 0% 0% 0% 1% 
Antiarrythmics 0% 0% 4% 1% 0% 0% 0% 1% 
Antianemics 0% 0% 0% 1% 0% 0% 0% 1% 
Hypoglycemics 0% 5% 8% 7% 0% 5% 0% 7% 
Antiepileptics 0% 0% 0% 1% 0% 0% 0% 1% 
Antitumorals 0% 0% 0% 2% 0% 0% 11% 2% 
Antibiotics 0% 0% 0% 1% 0% 0% 0% 1% 
Antidepressants 0% 0% 0% 100% 0% 0% 0% 0% 
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The pie chart (Graph 1) was used to indicate the MI events in patients exposed to montelukast 
1% and in subjects not taking montelukast, 6.25%, respectively. 
 
 
 
 
 
 
Graph 1. Graphic representation of MI events in sample A (asthmatic patients exposed to 
montelukast) compared to sample B (asthmatic patients not using montelukast) 
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Graph 2. Graphic representation of ischemic stroke (IS) events in sample A (asthmatic patients 
exposed to montelukast) compared to sample B (asthmatic patients not using montelukast) 
 
The pie chart (Graph 2) was used to indicate ischemic stroke events in patients exposed to 
montelukast 0.25 % and in subjects not taking montelukast, 2.25%. 
The MI event is 1% in patients exposed to montelukast and 6.25% in patients not taking 
montelukast, whereas ischemic stroke event in exposed patient is 0.25% with respect to 2.25% of 
unexposed patients. 
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Table 4. Fisher’s exact test tables for both a) ischemic stroke in exposed and unexpoxed samples 
and b) myocardial infarction 
a) 
  
No Ischemic 
stroke events 
Ischemic 
stroke events      Total 
Exposed 399 1 400 
Unexposed 391 9 400 
Total 790 10 800 
 
The p value calculated from the Fisher’s exact test equals 0.0207, less than 5%, and the null 
hypothesis is rejected, hence the treatment with montelukast affects the outcome, the predisposure to 
ischemic stroke event. 
b)  
  
No Myocardial 
infarction events 
Myocardial 
infarction 
events      Total 
Exposed 396 4 400 
Unexposed 375 25 400 
Total 771 29 800 
 
The p value calculated from the Fisher’s exact test is less than 0.0001 < 5%, so the null hypothesis is 
rejected, the treatment with montelukast can reduce the predisposure to MI event. 
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V- DISCUSSION 
 
This research illustrates two different approaches to CV risk reduction in inflammatory diseases. 
From one side we were focused on studying a possible new NSAID, a multitarget compound, 
displaying two different pharmacological profiles, in order to provide clear benefits on its safety 
and efficacy. Starting from the findings of Selg et. al [Selg E. et al., 2007], demonstrating a new 
and unrecognized mechanism of action of a traditional NSAID like diclofenac, and of its 
derivative lumiracoxib, which instead is a potent COXIB, both acting as TP antagonist 
eventhough with a potency too low for their effects to be appreciated in therapy (pA2 values in 
high micromolar range), new structural analogous of lumiracoxib were synthesized  [Bertinaria 
M. et al., 2012] and pharmacologically characterized [Hoxha M. et al., 2015]. Our intent was to 
provide new compounds displaying the COXIB activity in order to be used as antiinflammatory 
drugs, but increasing their potency as TP antagonist, so that we can obtain new compounds with 
predicted reduced CV side effects. Here we reported the pharmacological profile of some of the 
newly synthesized compounds, compound 18, the tetrazole derivative of lumiracoxib, the 
trifluoro methansulfonamido-isoster compound 20, compound 7 and compound 32, along with 
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the reference compounds diclofenac, an excellent analgesic [Todd PA. and Sorkin EM., 1988], 
and its derivative lumiracoxib, a potent COX-2 inhibitor, as well as of a traditional, non selective 
NSAID, naproxen. Pharmacological activities studies have shown that both the terazole 
derivative 18, as well as compound 20 are the most active TP antagonists with a decent balanced 
activity as COXIB and TP antagonist. 
 
We believe that this strategy would provide an additional benefit for patients with chronic pain 
and high GI risk taking a COXIB, as it will avoid the washed out period due to the increase in 
CV risk associated to COXIB use, or even in patients taking simultaneously a COXIB and low 
dose aspirin, due to the inhibition of the interaction of isoprostanes with TP receptor, something 
that is not provided from either of the treatments. Isoprostanes, non enzymatic products of AA, 
and extra-platelet TxA2 are produced in vivo, they do not respond or have a very scarce response 
to aspirin action [Audoly LP. et al., 2000], but their activity can be blocked by preventing their 
interaction with the TP receptor. Moreover, traditional NSAID, with the possible exclusion of 
naproxen, have also shown an increase of CV risks. Patients with diabetes or other high-risk 
vascular thrombotic disease have a basic demand for analgesic drugs that provide a GI and CV 
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safer profile. In addition, a dual COXIB-TP antagonist could also have a valuable use in 
chemoprevention, like colon adenoma prevention [Reddy BS. et al., 2005] based on the 
contribution of TxA2 synthesis in colon tumorigenesis [Sciulli MG. et al., 2005]. 
 
On the other hand, TP receptor antagonists and TxA2 biosynthesis inhibitors were not considered 
to be superior to the gold standard drug, aspirin [Cayette AJ. et al., 2000]. In addition, terutroban, 
a potent TP antagonist, despite presenting antithrombotic properties in peripheral arterial disease 
and improvement of endothelial function in atherosclerosis, did not result to be superior, but only 
similar to aspirin in the Perform Phase III clinical trial.  
 
Compound 32, studied in our lab was obtained by the replacement of 2-fluoro-6-chloro-phenyl 
substituent present on the amino nitrogen with the p-chlorophenylsulfonyl substructure, linking 
two phenyl rings by a sulfonamide group which, interestingly enough, is also present in 
terutroban. In the meanwhile, introducing a functional group of terutroban we expected that 
compound 32 would have displayed better properties, be a more potent TP antagonist with 
respect to other compound such as 7, 18 or 20; presumption   
72 
 
rejected by the results. In coherence with data in the literature, we observed that 2-amino-5-
methyl benzen carboxylic acid moiety is essential for the COX-2 selectivity. In terms of the TP 
antagonist properties both compounds 18 and 20 have shown an increase in TP receptor 
antagonist activity, highlighting the fact that in two different systems, inhibition of human 
platelets aggregation and IP generation, compound 20 resulted to be statistically different with 
respect to lumiracoxib, matching the affinity binding data previously reported [Bertinaria M. et 
al., 2012]. In addition these data suggest that the isosteric replacement of carboxylic function of 
lumiracoxib give rise to higher TP antagonistic activities of the compounds. This replacement 
can either be with cyclic or linear structures.  
The therapeutic effects of these new chemical entities endowed with a dualistic activity depend 
on the balance of two pharmacological profiles. Once again compound 18 and 20 resulted to be 
the most interesting compounds of the series, demonstrating better balanced activities (pA2 
TP/IC50 COX-2 = 179 and 3, respectively) with respect to the reference compounds lumiracoxib 
and diclofenac (pA2 TP/IC50 COX-2 = 2269 and 3619, respectively). Although naproxen, a non 
selective COX inhibitor, has a very weak TP receptor antagonism, it resulted to be safer for CV 
events with respect to others NSAID [Grosser T. et al., 2006]. Several studies have evidenced 
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that naproxen inhibits both systemic PGI2 biosynthesis [Graff J. et al., 2007], and platelet derived 
TxA2, hence not interfering with the equilibrium between TxA2 and PGI2, essential for designing 
a safer antiinflammatory drug. 
In conclusion, our data have shown that it is possible to obtain novel compounds starting from 
lumiracoxib, with higher TP antagonist potencies and better balanced COX-2 selectivity. In 
perspective, these new compounds may lead to a new class of NSAID with fewer CV side 
effects, with obvious pharmacokinetic and pharmacodynamic benefits displaying two of these 
activities at the same concentration range. After the bitter frustration and economic losses of 
pharmaceutical industries in the NSAID field due to the drawbacks of several COXIBs, we 
believe that the development of these dual compounds could represent a successful strategy to 
pursue. It is important to obtain innovative compounds with superior TP antagonist activity and 
better balanced COX activity to further investigate those in in vivo animal model. In particular, 
these dual compounds might have an impact in the therapeutic treatment of patients with higher 
CV risk that require a long term therapy with NSAIDs, like diabetics, or even in certain forms of 
cancer like colon cancer, or in chronic diseases like Alzheimer [Breitner JC. et al., 2011]. 
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On the other side, targeting others AA metabolites, such as cysteinyl-LTs involved in asthma and 
other inflammatory conditions including CV disorders [Funk CD., 2005], we thought it could 
add a new dimension to CV event reduction. In this context, we studied the effects of 
montelukast, a LT receptor antagonist (LTRA) drug, in the prevention of CV events (stroke and 
MI) in asthmatic patients. Thus, we performed a retrospective study including a total of eight 
hundred asthmatic patients exposed or not exposed to montelukast to assess the potential effect 
of this drug in the primary and secondary prevention of  a major CV event (manuscript in 
preparation). 
 
Somehow expected, the mean age of patients without a prior CV event, both exposed or not to 
montelukast, was almost 9 years lower with respect to patients with prior IS or MI, suggesting 
that age is a factor for an increased CV risk rate. In addition it is possible that females (both 
exposed or not to montelukast) can be more predisposed to IS (1.62 % vs 0.82% males). 
Data were recorded also for patients residence in urban or rural areas and accumulating results 
have shown that the majority of patients without prior CV event were resident in urban areas. 
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Regarding patients education level, overall, mid education level was predominant either in 
subjects without prior MI or IS, exposed or not to montelukast, or in patients with a history of IS 
events. Only patients unexposed to montelukast with a prior history of MI had a predominance of 
low education level, around 60%, whereas yearly income (mid and low) was very similar in the 
two patients groups, with a very low number of events in high income patients. Importantly, the 
percentages of the drug used in patients exposed or not to montelukast were very similar. The 
latter is essential to exclude potential confounders for the CV event rate. 
Overall, these results suggest that the MI and IS event rates were more than 6 fold and 9 fold 
higher, respectively, in asthmatic patients non taking montelukast with respect to patients 
exposed to it. These encouraging results, however, should be expanded to a larger number of 
patients, possibly to the whole Albanian asthmatic population. In addition, extending the 
treatment period with montelukast as well as the total exposure, should be implemented in 
further studies in order to provide a better overview of the whole patients clinical background 
and the real impact of the use of this drug. Moreover, further studies should also include data 
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regarding other risk factors such as obesity or smoking, regardless of the drug used monitored in 
the present study. 
Based on the results presented in this thesis we can foresee new innovative strategies for 
inflammatory disease like rheumatoid arthritis or carotid and coronary atherosclerosis by 
targeting specific components of the AA cascade. We believe that it is more and more evident 
that treatment of inflammation by a generalized inhibition of eicosanoid synthesis is a strategy 
far to be optimal. Nowadays there is still an unmet need for an adequate pain therapy conferring 
minimal GI damage and maximal cardioprotection. Furthermore, our montelukast study seems to 
suggest a novel therapeutic alternative for the prevention of the CV risk in the general 
population. In general terms, the pharmacological importance of compounds interfering with the 
inflammatory component is crucial for a different approach to CV diseases 
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